Literature DB >> 12185297

The use of chemotherapy in soft-tissue sarcomas.

Alexander I Spira1, David S Ettinger.   

Abstract

The treatment of advanced soft-tissue sarcomas is often palliative, although a subset of patients may be cured or have a long disease-free interval. This paper reviews the historical data over 30 years of treatment that has led to the use of ifosfamide and doxorubicin as the mainstay in the treatment of metastatic disease. These treatments have a high toxicity, relative to other chemotherapeutic regimens, with median response durations on the order of months. Agents developed in the last few years, whose role in the treatment of sarcomas is still evolving, are discussed as well. Finally, we discuss the role of chemotherapy in combination with surgery and radiation in the adjuvant and neoadjuvant settings.

Entities:  

Mesh:

Year:  2002        PMID: 12185297     DOI: 10.1634/theoncologist.7-4-348

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  33 in total

1.  A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Authors:  Christopher W Ryan; Chacon Matias; Mark Agulnik; Antonio Lopez-Pousa; Charles Williams; Dinesh P de Alwis; Christopher Kaiser; Mary Alice Miller; Sabine Ermisch; Robert Ilaria; M L Keohan
Journal:  Invest New Drugs       Date:  2012-04-27       Impact factor: 3.850

2.  Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1.

Authors:  Rieko Oyama; Fusako Kito; Marimu Sakumoto; Kumiko Shiozawa; Shunichi Toki; Makoto Endo; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-04-06       Impact factor: 2.416

3.  Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients.

Authors:  Kristoffer W Brudvik; Sameer H Patel; Christina L Roland; Claudius Conrad; Keila E Torres; Kelly K Hunt; Janice N Cormier; Barry W Feig; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2015-05-22       Impact factor: 3.452

4.  A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Authors:  Axel Le Cesne; Alejandro Yovine; Jean-Yves Blay; Suzette Delaloge; Robert G Maki; Jean-Louis Misset; Pilar Frontelo; Antonio Nieto; Juhui James Jiao; George D Demetri
Journal:  Invest New Drugs       Date:  2011-04-12       Impact factor: 3.850

Review 5.  Targeted therapy in sarcomas other than GIST tumors.

Authors:  Douglas Sborov; James L Chen
Journal:  J Surg Oncol       Date:  2014-10-20       Impact factor: 3.454

6.  An Unusual Case of Peritoneal Carcinomatosis.

Authors:  Stijn Hillewaere; Linde Stessens; Kurt Van der Speeten
Journal:  Case Rep Oncol       Date:  2010-09-09

7.  Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.

Authors:  Marc Becker; Claudine Graf; Marcus Tonak; Markus P Radsak; Tobias Bopp; Robert Bals; Rainer M Bohle; Matthias Theobald; Pol-Maria Rommens; Dirk Proschek; Thomas C Wehler
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

8.  Diffusion-weighted MRI of soft tissue tumours.

Authors:  Hildur Einarsdóttir; Magnus Karlsson; Johan Wejde; Henrik C F Bauer
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

9.  Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-03-29       Impact factor: 4.534

Review 10.  MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century.

Authors:  Igor Matushansky; Elizabeth Charytonowicz; Joslyn Mills; Sara Siddiqi; Todd Hricik; Carlos Cordon-Cardo
Journal:  Expert Rev Anticancer Ther       Date:  2009-08       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.